Reena Salgia, MD
Gastroenterology · Detroit, MINPI 1528180601
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,118 of the $111,891 with a category attached, or 60.9%. 16 manufacturers reported payments, led by Eisai Inc. at 31.4% of the total. Among gastroenterology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $1096.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$35K
- Exelixis Inc.$18K
- Gilead$16K
- E.r. Squibb & Sons, L.L.C.$14K
- AstraZeneca$11K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$6K
- plus $12K from 10 others
Across 157 payments — averaging $7506.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$541K
- Merck$519K
- AbbVie$64K
- Astrazeneca UK Limited$21K
- Bayer$20K
- E.r. Squibb & Sons, L.L.C.$12K
- plus $1K from 1 others
What the payments were for
- Consulting fees$38,64135%
- Speaking & faculty fees$68,11861%
- Grants$1880%
- Travel & lodging$2,0932%
- Food & beverage$2,8413%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 35 | $35,163 |
| Exelixis Inc. | 17 | $18,319 |
| Gilead | 17 | $15,669 |
| E.r. Squibb & Sons, L.L.C. | 8 | $13,950 |
| AstraZeneca | 6 | $10,726 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $5,900 |
| Cook Incorporated | 2 | $5,700 |
| Genentech USA, Inc. | 2 | $3,580 |
| Wilson Cook Medical Incorporated | 1 | $1,250 |
| Bristol Myers Squibb | 1 | $600 |
| Cook Medical LLC | 5 | $418 |
| Ardelyx, Inc. | 1 | $188 |
| Novartis | 1 | $123 |
| Boston Scientific | 1 | $118 |
| Biocompatibles, Inc. | 1 | $105 |
| Exact Sciences | 1 | $82 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$34,673
- Cabometyx$18,045
- OPDIVO$12,600
- XIFAXAN$10,900
- ECHOTIP INSIGHT$7,078
- IMFINZI$6,565
- Non-Covered Product$3,510
- Vemlidy$2,860
- IBSRELA$188
- THERASPHERE-BIO$105
How this compares
$111,891 in reported general payments places this provider in the 95th percentile of 497 gastroenterology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 50 | $1,187,234 |
| XifaxanRifaximin | 88 | $292,462 |
| Everolimus | 17 | $27,232 |
| Ursodiol | 137 | $26,603 |
| VemlidyTenofovir Alafenamide | 15 | $21,395 |
| Tacrolimus | 98 | $15,031 |
| EliquisApixaban | 17 | $14,702 |
| Mycophenolate Mofetil | 96 | $8,338 |
| Cyclosporine ModifiedCyclosporine, Modified | 40 | $7,006 |
| Azathioprine | 48 | $2,297 |
| Lactulose | 49 | $1,672 |
| Spironolactone | 67 | $992 |
| Tenofovir Disoproxil Fumarate | 17 | $665 |
| Prednisone | 43 | $283 |
| Pantoprazole Sodium | 31 | $274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $35,163 | $1,187,23450 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $5,900 | $292,46288 claims |
| GileadVemlidy | $15,669 | $21,39515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 497 gastroenterology providers in Michigan.
Other gastroenterology in Detroit
- Kimberly BrownDetroit$733K
- Dilip MoonkaDetroit$611K
- Stuart GordonDetroit$178K
- Milton MutchnickDetroit$106K
- Sumit SinglaDetroit$76K
- Nirmal KaurDetroit$59K
- Humberto Gonzalez GonzalezDetroit$53K
- Tobias ZuchelliDetroit$39K
- Juan Reyes GenereDetroit$37K
- Brian GinnebaughDetroit$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.